Re: USA ZHCLF investors
in response to
by
posted on
Nov 01, 2022 08:31AM
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
Zenith Capital Corporation 75 M shares has nothing to do with Zenith Epigenitics 138 M shares. I have 30,000 shares in Zenith Capitial Corporation and 0 in Zenith Epigentiics. Apples and oranges. This is how I understand it.